{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:00:37Z","timestamp":1771822837285,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,15]]},"DOI":"10.7759\/cureus.73729","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:22:13Z","timestamp":1731666133000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and Toxicity Profile of Reduced Dose Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Single Institutional Experience"],"prefix":"10.7759","author":[{"given":"Abhilash","family":"Menon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandini","family":"Devi R","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praveen K","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuprasad A","family":"Avaronnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allwin","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09578-1","article-title":"Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program","volume":"22","author":"Kulothungan V","year":"2022","unstructured":"Kulothungan V, Sathishkumar K, Leburu S, et al.. Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program. BMC Cancer. 2022, 22:527. 10.1186\/s12885-022-09578-1","journal-title":"BMC Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet JM","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al.. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359:378-90. 10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng AL","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al.. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology. 2009, 10:25-34. 10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02940.x","article-title":"First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study","volume":"66","author":"Lencioni R","year":"2012","unstructured":"Lencioni R, Kudo M, Ye SL, et al.. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012, 66:675-83. 10.1111\/j.1742-1241.2012.02940.x","journal-title":"Int J Clin Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3228","article-title":"Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: results from a Canadian Multicenter Database","volume":"9","author":"Alghamdi MA","year":"2020","unstructured":"Alghamdi MA, Amaro CP, Lee-Ying R, et al.. Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: results from a Canadian Multicenter Database. Cancer Med. 2020, 9:4918-28. 10.1002\/cam4.3228","journal-title":"Cancer Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2017.09.09","article-title":"The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology","volume":"6","author":"Touma JA","year":"2017","unstructured":"Touma JA, McLachlan AJ, Gross AS. The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology. Transl Cancer Res. 2017, 6:10.21037\/tcr.2017.09.09","journal-title":"Transl Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00248-X","article-title":"Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?","volume":"16","author":"Wong HH","year":"2015","unstructured":"Wong HH, Halford S. Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?. Lancet Oncology. 2015, 16:1287-8. 10.1016\/S1470-2045(15)00248-X","journal-title":"Lancet Oncology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000336082","article-title":"Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma","volume":"82","author":"Kim JE","year":"2012","unstructured":"Kim JE, Ryoo BY, Ryu MH, et al.. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma. Oncology. 2012, 82:119-25. 10.1159\/000336082","journal-title":"Oncology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.101447","article-title":"Epidemiology of hepatocellular carcinoma in India - an updated review for 2024","volume":"14","author":"Giri S","year":"2024","unstructured":"Giri S, Singh A. Epidemiology of hepatocellular carcinoma in India - an updated review for 2024. J Clin Exp Hepatol. 2024, 14:101447. 10.1016\/j.jceh.2024.101447","journal-title":"J Clin Exp Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo M","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al.. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018, 391:1163-73. 10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study","volume":"35","author":"Reiss KA","year":"2017","unstructured":"Reiss KA, Yu S, Mamtani R, et al.. Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study. J Clin Oncol. 2017, 35:3575-81. 10.1200\/JCO.2017.73.8245","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn RS","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al.. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020, 382:1894-905. 10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/sajc.sajc_44_17","article-title":"Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma","volume":"6","author":"Ostwal V","year":"2017","unstructured":"Ostwal V, Gupta T, Chopra S, et al.. Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma. South Asian J Cancer. 2017, 6:144-6. 10.4103\/sajc.sajc_44_17","journal-title":"South Asian J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa GK","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, et al.. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018, 379:54-63. 10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix J","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al.. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017, 389:56-66. 10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.780798","article-title":"Case report: durable response to very low dose tyrosine kinase inhibitors in advanced hepatocellular carcinoma","volume":"11","author":"Tang TY","year":"2021","unstructured":"Tang TY, Daunov K, Lee RT. Case report: durable response to very low dose tyrosine kinase inhibitors in advanced hepatocellular carcinoma. Front Oncol. 2021, 11:780798. 10.3389\/fonc.2021.780798","journal-title":"Front Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24644","article-title":"Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy","volume":"54","author":"Iavarone M","year":"2011","unstructured":"Iavarone M, Cabibbo G, Piscaglia F, et al.. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011, 54:2055-63. 10.1002\/hep.24644","journal-title":"Hepatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/315424-effectiveness-and-toxicity-profile-of-reduced-dose-sorafenib-for-the-treatment-of-hepatocellular-carcinoma-a-retrospective-single-institutional-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T10:22:14Z","timestamp":1731666134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/315424-effectiveness-and-toxicity-profile-of-reduced-dose-sorafenib-for-the-treatment-of-hepatocellular-carcinoma-a-retrospective-single-institutional-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.73729","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,15]]}}}